Clinical trial XL092-002 - Stellar 002
A Dose-Escalation and Expansion Study of the Safety and Efficacy of XL092 in Combination with Immuno-Oncology Agents in Subjects with Unresectable Advanced or Metastatic Solid Tumors
Organ | Colon |
---|---|
Trial status | Trial open for recruitment |
Investigator | |
Trial type |
Interventional with experimental drug
|
Phase | Trial phase 1/1b |
Academic trial | Non |
Sponsor | Exelixis |
EudraCT Identifier | 2021-004855-18 |
ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT05176483 |
Last update |